Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Octopus Biosafety Ltd. is a forward-looking company operating in the biotechnology and biosafety sector. Its primary focus is on developing, manufacturing, and supplying advanced biosafety solutions to prevent and control biological hazards. The company's innovative technologies play a crucial role in enhancing workplace safety across diverse industries such as healthcare, agriculture, and food processing. By deploying state-of-the-art decontamination systems and air purification equipment, Octopus Biosafety Ltd. helps organizations minimize risks associated with pathogenic threats and contamination. In the market context, the company stands out as a significant contributor to public health and occupational safety, meeting the increasing global demand for effective biosafety measures. Its commitment to innovation and safety positions it as a key player in fortifying defenses against biological risk factors worldwide.
The business is unprofitable at the operating level (-1029.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 77.2% YoY. Margins deteriorated 684.8pp alongside, both lines moving the wrong way.
ROIC dropped from -40.94% to -94.19%, capital efficiency is deteriorating. Operating margin contracted 684.8pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
€52K
▼ -77.2% YoY
Net Income (TTM)
-€659K
▲ +62.9% YoY
Op. Margin
-1029.55%
▼ -684.8pp YoY
ROIC
-94.19%
▼ -53.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
€524K
Cash & Equiv.
€23K
3Y CAGR: -7.8%
Continue Research